SCHEMBL6165568

SCHEMBL6165568

COc1ccc(C)cc1Nc1nc2ccc(CC(=O)N(C)c3ccc(C(C)CC(=O)O)nc3)cc2o1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.38
TP53 P04637 1/20 0.38
ITGA4 P13612 8/20 0.34
RXFP1 Q9HBX9 2/20 0.34
CYP1A2 P05177 1/20 0.34
RAB9A P51151 1/20 0.34
ITGB1 P05556 2/20 0.33
GAA P10253 2/20 0.33
INSR P06213 1/20 0.32
ALK Q9UM73 1/20 0.32
KCNH2 Q12809 1/20 0.32
KDM4E B2RXH2 2/20 0.32
HPGD P15428 2/20 0.32
HSD17B10 Q99714 2/20 0.32
TSHR P16473 1/20 0.32
ALDH1A1 P00352 2/20 0.32
LMNA P02545 1/20 0.32
AGTR1 P30556 1/20 0.32
OPRK1 P41145 1/20 0.32
MDM2 Q00987 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6163439 0.91 ITGA4 (0.38) MAPTTP53ITGA4ITGB1INSR
SCHEMBL6165498 0.86 ITGA4 (0.46) MAPTTP53ITGA4RAB9AITGB1
SCHEMBL6164434 0.86 TP53 (0.38) MAPTTP53ITGA4RXFP1ITGB1
SCHEMBL6163004 0.85 MAPT (0.43) MAPTTP53ITGA4RXFP1RAB9A
SCHEMBL6163942 0.85 ITGA4 (0.41) MAPTTP53ITGA4RAB9AITGB1
SCHEMBL6162946 0.85 ITGA4 (0.39) MAPTTP53ITGA4RAB9AITGB1
SCHEMBL6165563 0.85 MAPT (0.39) MAPTTP53ITGA4RXFP1CYP1A2
SCHEMBL6162933 0.85 ITGA4 (0.38) ITGA4ITGB1
SCHEMBL6163118 0.84 IL6 (0.37) MAPTITGA4RAB9AITGB1GAA
SCHEMBL6167396 0.84 MAPT (0.42) MAPTRAB9AGAAMEN1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1183254-B1 SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS AS INTEGRIN ANTAGONISTS AVENTIS PHARMA LTD (GB) 2005-01-12 EP disclosed
US-6706738-B2 ANTIARTHRITIC AGENTS; ANTIINFLAMMATORY AGENTS AVENTIS PHARMA LIMITED (GB) 2004-03-16 US disclosed
US-20020173506-A1 Substituted bicyclic heteroaryl compounds and their use as integrin antagonists AVENTIS PHARMA LIMITED (GB) 2002-11-21 US disclosed
EP-1183254-A1 SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS AS INTEGRIN ANTAGONISTS Aventis Pharma Limited (GB) 2002-03-06 EP disclosed
WO-2000061580-A1 SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS AS INTEGRIN ANTAGONISTS AVENTIS PHARMA LIMITED (GB) 2000-10-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020173506-A1 Substituted bicyclic heteroaryl compounds and their use as integrin antagonists VCAM1, ITGA4, ITGA1 MAPT 4812/4885TP53 3768/4885ITGA4 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.